2020年法国风湿病学会痛风管理建议:急性发作的处理
法国风湿病学会基于系统文献检索、一次会议起草和两轮德尔菲法,制定了4条总体原则和4条推荐,用于痛风急性发作的管理。总体原则强调患者教育(尽早自行用药、痛风为慢性病常需降尿酸治疗)、仔细筛查合并症和药物相互作用。推荐秋水仙碱早期使用(1mg,1小时后0.5mg,之后0.5mg每日2-3次),腹泻时减量,慢性肾脏病或合用干扰其代谢药物时减量;其他一线选择为全身/关节腔糖皮质激素或非甾体抗炎药;IL-1抑制剂可作为二线选择,感染时禁用并监测中性粒细胞计数。
要点
- 痛风发作应尽早自行用药,最好在发作后12小时内,按预先定义的方案治疗。
- 秋水仙碱剂量:首剂1mg,1小时后0.5mg,之后0.5mg每日2-3次,用数天。
- 出现腹泻(秋水仙碱中毒的首个症状)时必须减量;慢性肾脏病或合用干扰秋水仙碱代谢的药物时也需减量。
- 其他一线选择为全身或关节腔糖皮质激素,或非甾体抗炎药。
- IL-1抑制剂可作为二线选择(秋水仙碱、糖皮质激素和非甾体抗炎药失败、不耐受或禁忌时),感染时禁用,并监测中性粒细胞计数。
适用人群与场景
- 痛风急性发作患者。
- 需仔细筛查合并症和药物相互作用,因其可能禁忌某些抗炎治疗。
处置流程与药物剂量
- 秋水仙碱应早期处方,剂量为1mg,1小时后0.5mg,之后0.5mg每日2-3次,用数天。
- 出现腹泻(秋水仙碱中毒的首个症状)时必须减量。
- 慢性肾脏病患者或使用干扰秋水仙碱代谢的药物时,秋水仙碱剂量必须减少。
- 其他一线治疗选择为全身或关节腔糖皮质激素,或非甾体抗炎药。
- IL-1抑制剂可考虑作为二线选择,用于秋水仙碱、糖皮质激素和非甾体抗炎药失败、不耐受或禁忌时;感染时禁用,并应监测中性粒细胞计数。
红旗征与不能漏的情况
- 腹泻是秋水仙碱中毒的首个症状,出现时必须减量。
- IL-1抑制剂在感染情况下禁用。
研究设计与关键结果
- 制定4条总体原则和4条推荐。
- 总体原则强调患者教育,包括按预定方案尽早自行用药(最好在发作后12小时内),并了解痛风是慢性病、常需降尿酸治疗。
- 总体原则强调每位患者应仔细筛查合并症和药物相互作用,因其可能禁忌某些抗炎治疗。
证据类型、等级与局限
- 证据类型:指南(法国风湿病学会)。
- 方法:系统文献检索,一次实体会议起草推荐,两轮德尔菲法最终确定。
- 制定小组:9名风湿科医生(学术或社区)、3名全科医生、1名心脏病医生、1名肾脏病医生和1名患者。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为应教育痛风患者在发作后尽早(最好12小时内)按预定方案自行用药。
- 作者认为应筛查合并症和药物相互作用,因其可能禁忌某些抗炎治疗。
- 作者认为秋水仙碱应早期使用,剂量为1mg后1小时0.5mg,之后0.5mg每日2-3次;腹泻时减量,慢性肾脏病或合用干扰代谢药物时减量。
- 作者认为全身/关节腔糖皮质激素或非甾体抗炎药可作为其他一线选择。
- 作者认为IL-1抑制剂可考虑作为二线选择(失败、不耐受或禁忌时),感染时禁用并监测中性粒细胞计数。
指南或共识出处
- 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares(法国风湿病学会,2020年)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop French Society of Rheumatology-endorsed recommendations for the management of gout flares.
METHODS: These evidence-based recommendations were developed by 9 rheumatologists (academic or community-based), 3 general practitioners, 1 cardiologist, 1 nephrologist and 1 patient, using a systematic literature search, one physical meeting to draft recommendations and 2 Delphi rounds to finalize them.
RESULTS: A set of 4 overarching principles and 4 recommendations was elaborated. The overarching principles emphasize the importance of patient education, including the need to auto-medicate for gout flares as early as possible, if possible within the first 12h after the onset, according to a pre-defined treatment. Patients must know that gout is a chronic disease, often requiring urate-lowering therapy in addition to flare treatment. Comorbidities and the risk of drug interaction should be screened carefully in every patient as they may contraindicate some anti-inflammatory treatments. Colchicine must be early prescribed at the following dosage: 1mg then 0.5mg one hour later, followed by 0.5mg,2 to 3 times/day over the next days. In case of diarrhea, which is the first symptom of colchicine poisoning, dosage must be reduced. Colchicine dosage must also be reduced in patients with chronic kidney disease or taking drugs, which interfere with its metabolism. Other first-line treatment options are systemic/intra-articular corticosteroids, or non-steroidal anti-inflammatory agents (NSAIDs). IL-1 inhibitors can be considered as a second-line option in case of failure, intolerance or contraindication to colchicine, corticosteroids and NSAIDs. They are contraindicated in cases of infection and neutrophil blood count should be monitored.
CONCLUSION: These recommendations aim to provide strategies for the safe use of anti-inflammatory agents, in order to improve the management of gout flares.
参考来源
- Latourte A, Pascart T, Flipo RM, et al. 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine. 2020. PMID: 32422339. doi:10.1016/j.jbspin.2020.05.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。